1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% of fatalities were thought to be due to liso-cel related complications. Evidence Rating Level: 1 (Excellent) Study Rundown: There exist limited options for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic
1. Mean MADRS change at week 6 was -8.2 in the active tDCS group versus -8.0 in the sham tDCS group. 2. There were significantly more adverse events in the active tDCS group. Evidence Rating Level: 1 (Excellent) Study Rundown: Transcranial direct current stimulation (tDCS) has been proposed as a feasible treatment for major depressive disorder (MDD),
1. Mean MADRS change at week 6 was -8.2 in the active tDCS group versus -8.0 in the sham tDCS group. 2. There were significantly more adverse events in the active tDCS group. Evidence Rating Level: 1 (Excellent) Study Rundown: Transcranial direct current stimulation (tDCS) has been proposed as a feasible treatment for major depressive
1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no treatment-related fatalities among patients in the talazoparib group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer is the second most common malignancy among men. Despite existing therapies, metastatic castration-resistant prostate cancer (mCRPC) remains a